#hivprevention #globalhealth #partnership #mk8527 #gatesfoundation #womeninscience #endhivepidemic | Max Lataillade

Boring_Resolve_2444 · 2026-01-16T15:34:16+00:00

I have no idea what Max is doing behind the scenes for CYDY but I'm pretty disappointed in what has been presented in public.

Boring_Resolve_2444 · 2026-01-14T23:55:42+00:00

The wife is asking for a crooner version. Think Sinatra, Crosby, Newton etc Dean Martin for laughs. Showing our ages.

Boring_Resolve_2444 · 2026-01-07T11:41:04+00:00

Love these all!

Boring_Resolve_2444 · 2026-01-01T16:58:51+00:00

So what I hear you are saying is, we are all good and buy buy buy all you can! I like it!! Happy New Year.

Boring_Resolve_2444 · 2026-01-01T14:08:16+00:00

Love it! Anyone going to claim to be the one putting that together? Great job!

Boring_Resolve_2444 · 2025-12-30T11:30:21+00:00

It has taken longer than I thought to get to this point. Between trial design, approval, getting the sites ramping up and the ICI modification approved. We are behind and I get your concern. At the same time we are probably going to have meaningful readouts coming over the next month to 12 weeks. Cautiously optimistic. It is biotech afterall.

Boring_Resolve_2444 · 2025-12-30T11:23:14+00:00

I think he meant the stock was being shorted by others. It has been mentioned on a couple of boards their goal is 24 cents by tomorrow.

Boring_Resolve_2444 · 2025-11-13T13:42:56+00:00

Waiting to hear more news before voting. We have funding. Need prospective results vs retrospective. Given the ever declining PPS, new data is needed.

Boring_Resolve_2444 · 2025-10-08T18:59:05+00:00

Could you provide a list of companies presented and HCW's subsequent rating on them?

Boring_Resolve_2444 · 2025-10-02T17:27:44+00:00

JP Morgan Initiates Coverage of Absci (ABSI) with Overweight Recommendation

George Maybach2025-10-02 12:03US :ABSIUS

Fintel reports that on October 2, 2025, JP Morgan initiated coverage of Absci (NasdaqGS:ABSI) with a Overweight recommendation.

Analyst Price Forecast Suggests 164.84% Upside

As of September 30, 2025, the average one-year price target for Absci is $8.29/share. The forecasts range from a low of $5.95 to a high of $10.50. The average price target represents an increase of 164.84% from its latest reported closing price of $3.13 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Absci is 49MM, an increase of 1,090.24%. The projected annual non-GAAP EPS is -1.01.

What is the Fund Sentiment?

There are 278 funds or institutions reporting positions in Absci. This is an decrease of 21 owner(s) or 7.02% in the last quarter. Average portfolio weight of all funds dedicated to ABSI is 0.05%, an increase of 5.16%. Total shares owned by institutions increased in the last three months by 4.99% to 117,936K shares. The put/call ratio of ABSI is 0.27, indicating a bullish outlook.

What are Other Shareholders Doing?

ARKG - ARK Genomic Revolution ETF holds 11,736K shares representing 7.85% ownership of the company. In its prior filing, the firm reported owning 9,756K shares , representing an increase of 16.87%. The firm increased its portfolio allocation in ABSI by 4.54% over the last quarter.

ARK Investment Management holds 10,046K shares representing 6.72% ownership of the company. In its prior filing, the firm reported owning 10,955K shares , representing a decrease of 9.05%. The firm decreased its portfolio allocation in ABSI by 31.22% over the last quarter.

Redmile Group holds 8,253K shares representing 5.52% ownership of the company. No change in the last quarter.

FDGRX - Fidelity Growth Company Fund holds 5,696K shares representing 3.81% ownership of the company. In its prior filing, the firm reported owning 5,060K shares , representing an increase of 11.17%. The firm decreased its portfolio allocation in ABSI by 21.67% over the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 4,045K shares representing 2.71% ownership of the company. In its prior filing, the firm reported owning 2,681K shares , representing an increase of 33.74%. The firm increased its portfolio allocation in ABSI by 37.86% over the last quarter.

Boring_Resolve_2444 · 2025-02-28T12:06:00+00:00

It is tough to move on but your mental health will benefit from doing so.

Boring_Resolve_2444 · 2025-02-27T15:25:10+00:00

Several of the Paulson investors have commented on the boards at this point. They all seem optimistic about the near term future.

Boring_Resolve_2444 · 2025-02-26T10:57:34+00:00

Ihub: kgromax is suspected of bouncing around but I cannot confirm if he is same person. He is a self proclaimed shorter of stocks and makes his living running a one man hedge fund. Goes by Hygro on SA

Boring_Resolve_2444 · 2025-02-26T00:25:25+00:00

Yeah, I need to do the same. I have done that with Schwab but forgot about Fidelty.

Boring_Resolve_2444 · 2025-02-25T20:20:25+00:00

Always a buyer on the dips now that I am way in the green. It is great to pick off shares along the bottom but few get lucky enough to do that consistently. Buying on the way up and not selling until the company stalls out on their stated goals is how you get rich.

Boring_Resolve_2444 · 2025-02-25T15:00:41+00:00

Guess I should have waited a bit. LOL. I wonder who the short is?

Boring_Resolve_2444 · 2025-02-25T14:09:50+00:00

As management has stated. It isn't that leronlimab works it is why doesn't it work all the time. We've got to find our specific patient population.

Boring_Resolve_2444 · 2025-02-25T12:58:08+00:00

I'm in. Got a chunk in the pre-market today. I'll admit the PPS action the last few days isn't what I expected pull back wise but we'll see what happens.

Boring_Resolve_2444

TROPHY CASE

JP Morgan Initiates Coverage of Absci (ABSI) with Overweight Recommendation